Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024

Description

Treatment for glioblastoma multiforme (GBM) involves managing and caring for patients with this rapidly growing brain or spinal cord tumor. Adults diagnosed with this primary malignant brain tumor face the highest prevalence rate.

The primary treatments for glioblastoma multiforme (GBM) include surgery, radiation therapy, chemotherapy, targeted therapy, tumor-treating field (TTF) therapy, and immunotherapy. Surgery is a medical discipline that concentrates on employing manual and instrumental methods to treat wounds, illnesses, and other conditions. The types of drugs involved in GBM treatment include temozolomide, bevacizumab, lomustine, carmustine wafers, and others. These medications are administered through oral, parenteral, and various other routes of administration and are used by hospitals, clinics, and ambulatory surgical centers.

The glioblastoma multiforme (GBM) treatment market research report is one of a series of new reports from The Business Research Company that provides glioblastoma multiforme (GBM) treatment market statistics, including glioblastoma multiforme (GBM) treatment industry global market size, regional shares, competitors with glioblastoma multiforme (GBM) treatment market share, detailed glioblastoma multiforme (GBM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (GBM) treatment industry. This glioblastoma multiforme (GBM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glioblastoma multiforme (gbm) treatment market size has grown rapidly in recent years. It will grow from $2.23 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The increase during the historical period can be credited to the increased incidence and prevalence of the condition, advancements in diagnostic techniques, funding for clinical trials and research, collaborations and partnerships in the medical field, and an enhanced understanding of tumor biology.

The glioblastoma multiforme (gbm) treatment market size is expected to see rapid growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The anticipated growth in the forecast period can be ascribed to the emergence of immunotherapies, advancements in precision medicine, an expanded understanding of genetic markers, increased patient advocacy and awareness, and government support for rare diseases. Key trends expected in the forecast period encompass the exploration of combination therapies, the integration of artificial intelligence in diagnosis and treatment planning, a rise in the adoption of immunotherapeutic approaches, and advancements in medical tools and equipment.

The growth of the glioblastoma multiforme (GBM) treatment market is expected to be fueled by the increasing prevalence of brain disorders. Brain disorders, including GBM, result from various factors such as aging populations, compromised immune systems, overdiagnosis, ionizing radiation, and air pollution. The need for treating brain disorders has intensified due to their impact on well-being. Globally, approximately 308,102 cancer cases related to the brain and central nervous system were detected in 2020, according to Globocan. The American Cancer Society estimates around 25,050 new malignant tumors of the brain or spinal cord cancer cases in the US in 2022. Thus, the rising prevalence of brain disorders is a key driver of the GBM treatment market.

The glioblastoma multiforme (GBM) treatment market is expected to grow due to the rising geriatric population. The elderly, aged 65 and older, present specific health considerations, leading to the development of treatment strategies tailored for older patients with GBM. According to the World Health Organization, by 2030, 1 in 6 individuals globally will be 60 or older, reaching 2.1 billion elderly people by 2050. This demographic shift is a key factor propelling the growth of the GBM treatment market.

Advancements in therapies are gaining popularity as major companies invest in research and development for innovative treatments. In November 2021, Daiichi Sankyo Company Limited, a Japanese pharmaceutical company, launched DELYTACT, the first oncolytic virus-based immunotherapy (Teserpaturev) in collaboration with the Institute of Medical Science, The University of Tokyo. DELYTACT uses genetically modified viruses to infect and replicate in cancer cells, triggering multiple mechanisms of the patient's immune system to produce immune-boosting molecules and initiate anti-cancer immunity.

Major companies are prioritizing innovative treatments such as radiopharmaceutical therapy to meet the demand for advanced and targeted therapeutic solutions. Radiopharmaceutical therapy involves using radioactive substances to deliver targeted radiation to specific tissues or cells, commonly employed in cancer treatment to destroy cancer cells. For instance, in February 2022, Theragnostics, a UK-based provider of molecular radiotherapy and molecular imaging diagnostic products, announced the development of I-123 PARPi (THG-009) therapy. This innovative therapy, granted an Innovation Passport by the UK MHRA, aims to address primary and recurrent Glioblastoma Multiforme (GBM) and is advancing to a Phase 1 clinical trial.

In April 2022, Elekta, a Sweden-based company providing radiation therapy, radiosurgery, related equipment, and clinical management for cancer treatment, signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals. This collaboration enables them to offer comprehensive solutions across imaging and treatment for cancer patients requiring radiation therapy. The partnership facilitates the joint promotion of solutions tailored to the needs of each cancer center.

Major companies operating in the glioblastoma multiforme (gbm) treatment market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Carl Zeiss AG, Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Arbor Pharmaceuticals LLC, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc., Angiochem Inc., Diffusion Pharmaceuticals Inc.

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glioblastoma multiforme (gbm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glioblastoma multiforme (gbm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glioblastoma multiforme (gbm) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glioblastoma multiforme (gbm) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Tumor Treating Field (TTF) Therapy; Immunotherapy
2) By Drug Class: Temozolomide; Bevacizumab; Lomustine; Carmustine Wafers; Other Drug Classes
3) By Route of Administration: Oral; Parenteral; Other Route Of Administrations
4) By End-Use: Hospitals; Clinics; Ambulatory Surgical Centers
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r15658

1. Executive Summary

2. Glioblastoma Multiforme (GBM) Treatment Market Characteristics

3. Glioblastoma Multiforme (GBM) Treatment Market Trends And Strategies

4. Glioblastoma Multiforme (GBM) Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Glioblastoma Multiforme (GBM) Treatment Market Size and Growth

5.1. Global Glioblastoma Multiforme (GBM) Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Glioblastoma Multiforme (GBM) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Glioblastoma Multiforme (GBM) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Glioblastoma Multiforme (GBM) Treatment Market Segmentation

6.1. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Tumor Treating Field (TTF) Therapy
Immunotherapy
6.2. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Temozolomide
Bevacizumab
Lomustine
Carmustine Wafers
Other Drug Classes
6.3. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Other Route Of Administrations
6.4. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Ambulatory Surgical Centers

7. Glioblastoma Multiforme (GBM) Treatment Market Regional And Country Analysis

7.1. Global Glioblastoma Multiforme (GBM) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Glioblastoma Multiforme (GBM) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market

8.1. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Glioblastoma Multiforme (GBM) Treatment Market

9.1. China Glioblastoma Multiforme (GBM) Treatment Market Overview
9.2. China Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Glioblastoma Multiforme (GBM) Treatment Market

10.1. India Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Glioblastoma Multiforme (GBM) Treatment Market

11.1. Japan Glioblastoma Multiforme (GBM) Treatment Market Overview
11.2. Japan Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Glioblastoma Multiforme (GBM) Treatment Market

12.1. Australia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Glioblastoma Multiforme (GBM) Treatment Market

13.1. Indonesia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Glioblastoma Multiforme (GBM) Treatment Market

14.1. South Korea Glioblastoma Multiforme (GBM) Treatment Market Overview
14.2. South Korea Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Glioblastoma Multiforme (GBM) Treatment Market

15.1. Western Europe Glioblastoma Multiforme (GBM) Treatment Market Overview
15.2. Western Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Glioblastoma Multiforme (GBM) Treatment Market

16.1. UK Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Glioblastoma Multiforme (GBM) Treatment Market

17.1. Germany Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Glioblastoma Multiforme (GBM) Treatment Market

18.1. France Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Glioblastoma Multiforme (GBM) Treatment Market

19.1. Italy Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Glioblastoma Multiforme (GBM) Treatment Market

20.1. Spain Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market

21.1. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market Overview
21.2. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Glioblastoma Multiforme (GBM) Treatment Market

22.1. Russia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Glioblastoma Multiforme (GBM) Treatment Market

23.1. North America Glioblastoma Multiforme (GBM) Treatment Market Overview
23.2. North America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Glioblastoma Multiforme (GBM) Treatment Market

24.1. USA Glioblastoma Multiforme (GBM) Treatment Market Overview
24.2. USA Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Glioblastoma Multiforme (GBM) Treatment Market

25.1. Canada Glioblastoma Multiforme (GBM) Treatment Market Overview
25.2. Canada Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Glioblastoma Multiforme (GBM) Treatment Market

26.1. South America Glioblastoma Multiforme (GBM) Treatment Market Overview
26.2. South America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Glioblastoma Multiforme (GBM) Treatment Market

27.1. Brazil Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Glioblastoma Multiforme (GBM) Treatment Market

28.1. Middle East Glioblastoma Multiforme (GBM) Treatment Market Overview
28.2. Middle East Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Glioblastoma Multiforme (GBM) Treatment Market

29.1. Africa Glioblastoma Multiforme (GBM) Treatment Market Overview
29.2. Africa Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape And Company Profiles

30.1. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape
30.2. Glioblastoma Multiforme (GBM) Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Glioblastoma Multiforme (GBM) Treatment Market Other Major And Innovative Companies

31.1. AstraZeneca PLC
31.2. Amgen Inc.
31.3. Teva Pharmaceutical Industries Ltd.
31.4. Carl Zeiss AG
31.5. Sun Pharmaceutical Industries Limited
31.6. Jazz Pharmaceuticals Inc.
31.7. Sumitomo Dainippon Pharma Oncology Inc.
31.8. Varian Medical Systems Inc.
31.9. Amneal Pharmaceuticals Inc.
31.10. Elekta AB
31.11. ANI Pharmaceuticals Inc.
31.12. Accord Healthcare Limited
31.13. The Eckert & Ziegler Group
31.14. Arbor Pharmaceuticals LLC
31.15. Loxo Oncology Inc.

32. Global Glioblastoma Multiforme (GBM) Treatment Market Competitive Benchmarking

33. Global Glioblastoma Multiforme (GBM) Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Glioblastoma Multiforme (GBM) Treatment Market

35. Glioblastoma Multiforme (GBM) Treatment Market Future Outlook and Potential Analysis

35.1 Glioblastoma Multiforme (GBM) Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Glioblastoma Multiforme (GBM) Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Glioblastoma Multiforme (GBM) Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer